Australian public assessment report for Dolutegravir (as sodium)
... In 2011 there were an estimated 34.2 million adults and children with HIV infection, with 2.5 million new infections and 1.7 million deaths annually. The epidemic has stabilised in most developed countries but the prevalence continues to rise in Central Europe, Asia and Sub-Saharan Africa. Progressi ...
... In 2011 there were an estimated 34.2 million adults and children with HIV infection, with 2.5 million new infections and 1.7 million deaths annually. The epidemic has stabilised in most developed countries but the prevalence continues to rise in Central Europe, Asia and Sub-Saharan Africa. Progressi ...
Aminophylline
... 12 mg/litre. For further information on the dosage of theophylline itself in neonates, see Administration in Infants, ...
... 12 mg/litre. For further information on the dosage of theophylline itself in neonates, see Administration in Infants, ...
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
... The exact mechanism of hydrochlorothiazide's antihypertensive action is not known although it may relate to the excretion and redistribution of body sodium. Hydrochlorothiazide does not affect normal blood pressure. Following oral administration, peak hydrochlorothiazide plasma levels are attained i ...
... The exact mechanism of hydrochlorothiazide's antihypertensive action is not known although it may relate to the excretion and redistribution of body sodium. Hydrochlorothiazide does not affect normal blood pressure. Following oral administration, peak hydrochlorothiazide plasma levels are attained i ...
DRUGDEX DRUG EVALUATIONS
... John's Wort, causing increased metabolism and consequent lowering of ethynyloestradiol concentrations (Ernst, 1999). c. St. John's Wort significantly increased P-glycoprotein expression and associated drug efflux in a randomized, single-blind, placebo-controlled trial of 22 healthy subjects (13 fema ...
... John's Wort, causing increased metabolism and consequent lowering of ethynyloestradiol concentrations (Ernst, 1999). c. St. John's Wort significantly increased P-glycoprotein expression and associated drug efflux in a randomized, single-blind, placebo-controlled trial of 22 healthy subjects (13 fema ...
Extract from Clinical Evaluation Report: Ivermectin
... fed and fasted subjects reveals that bioavailability of ivermectin in the fasted state is at most approximately 40%, allowing ample margin for variability in absorption. Comments: The parallel design of the study may also have contributed to the variability in AUC and Cmax observed across doses. Tma ...
... fed and fasted subjects reveals that bioavailability of ivermectin in the fasted state is at most approximately 40%, allowing ample margin for variability in absorption. Comments: The parallel design of the study may also have contributed to the variability in AUC and Cmax observed across doses. Tma ...
Buprenorphine (with or without naloxone)
... illicit ‘use on top’. However, if illicit opioids are used, they will produce additional opioid effects if they are able to reach the receptor sites. Buprenorphine, with its high affinity for the opioid receptor sites blocks other opioids from the receptor site while it is present (Ling et al 1998). ...
... illicit ‘use on top’. However, if illicit opioids are used, they will produce additional opioid effects if they are able to reach the receptor sites. Buprenorphine, with its high affinity for the opioid receptor sites blocks other opioids from the receptor site while it is present (Ling et al 1998). ...
Pharmacological effects of meldonium: Biochemical mechanisms
... Fig. 1. The role of l-carnitine in fatty acid transport and mitochondrial energy metabolism pathways. Fatty acid (FA) is activated to corresponding acyl-coenzyme A (Acyl-CoA) via long-chain acyl-coenzyme A synthetase (ACS). Then, l-carnitine facilitates acyl-CoA transport into the mitochondria via c ...
... Fig. 1. The role of l-carnitine in fatty acid transport and mitochondrial energy metabolism pathways. Fatty acid (FA) is activated to corresponding acyl-coenzyme A (Acyl-CoA) via long-chain acyl-coenzyme A synthetase (ACS). Then, l-carnitine facilitates acyl-CoA transport into the mitochondria via c ...
Bioavailability & Bioequivalence
... reabsorption usually occurs in the proximal tubule Appearance of drug in the urine is the net result of filtration, secretion, and reabsorption ...
... reabsorption usually occurs in the proximal tubule Appearance of drug in the urine is the net result of filtration, secretion, and reabsorption ...
Clorhidrato de Propranolol. Monografia del farmaco.
... Approximately 90% of circulating propranolol is bound to plasma proteins (albumin and alpha1 acid glycoprotein). The binding is enantiomer-selective. The S(-)-enantiomer is preferentially bound to alpha1 glycoprotein and the R(+)enantiomer preferentially bound to albumin. The volume of distribution ...
... Approximately 90% of circulating propranolol is bound to plasma proteins (albumin and alpha1 acid glycoprotein). The binding is enantiomer-selective. The S(-)-enantiomer is preferentially bound to alpha1 glycoprotein and the R(+)enantiomer preferentially bound to albumin. The volume of distribution ...
levocarb CR
... been established. Use in Pregnancy and Lactation Although the effects of levodopa/carbidopa controlled-release tablets on human pregnancy and lactation are unknown, both levodopa and combinations of levodopa and carbidopa have caused visceral and skeletal malformations in rabbits (see TOXICOLOGY, Te ...
... been established. Use in Pregnancy and Lactation Although the effects of levodopa/carbidopa controlled-release tablets on human pregnancy and lactation are unknown, both levodopa and combinations of levodopa and carbidopa have caused visceral and skeletal malformations in rabbits (see TOXICOLOGY, Te ...
Colloidal Submicron-Particle Curcumin Exhibits High Absorption
... phospholipid formulation, produced with a lecithinized formation method. Curcumin is covered by phospholipid particles at its surface and has been shown to strongly bind to phospholipid micelles, positioning the waterlabile -diketone moiety in the lipid bilayer and protecting it from hydrolytic fra ...
... phospholipid formulation, produced with a lecithinized formation method. Curcumin is covered by phospholipid particles at its surface and has been shown to strongly bind to phospholipid micelles, positioning the waterlabile -diketone moiety in the lipid bilayer and protecting it from hydrolytic fra ...
CIPRO XL PRODUCT MONOGRAPH
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
PrCIPRO® XL - Bayer Canada
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
idarubicin
... idarubicin total cumulative doses up to 400 mg/m2 suggest a low probability of cardiotoxicity. Cardiac function should be assessed before patients undergo treatment with idarubicin and must be monitored throughout therapy to minimize the risk of incurring severe cardiac impairment. The risk may be d ...
... idarubicin total cumulative doses up to 400 mg/m2 suggest a low probability of cardiotoxicity. Cardiac function should be assessed before patients undergo treatment with idarubicin and must be monitored throughout therapy to minimize the risk of incurring severe cardiac impairment. The risk may be d ...
Clearing of Metabolic Waste via Enterohepatic Recirculation Table
... elimination of the molecule from the body which can also show a prolonged effect enhanced by its binding to plasmatic proteins. (Latruffe et al. 2006) In this case, the enterohepatic recirculation would be beneficial in preventing or delaying cancer growth as repeated exposure to the resveratrol is ...
... elimination of the molecule from the body which can also show a prolonged effect enhanced by its binding to plasmatic proteins. (Latruffe et al. 2006) In this case, the enterohepatic recirculation would be beneficial in preventing or delaying cancer growth as repeated exposure to the resveratrol is ...
DOXOrubicin vials - Sagent Pharmaceuticals
... The recommended dose of doxorubicin HCl is 60 mg/m2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles [see Clinical Studies (14)]. Metastatic Disease, Leukemia, or Lymphoma ...
... The recommended dose of doxorubicin HCl is 60 mg/m2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles [see Clinical Studies (14)]. Metastatic Disease, Leukemia, or Lymphoma ...
PrCIPRO® XL
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
Full Product Information
... After oral administration, salbutamol is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine. The bioavailability of orally administered salbutamol is about 50%. Pre- ...
... After oral administration, salbutamol is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine. The bioavailability of orally administered salbutamol is about 50%. Pre- ...
Clinical overview - WHO archives
... There are different ways to combine antimalarial drugs. Compliance with sequential combination regimen is notoriously poor; patients are reluctant to take antimalarials after they feel well. Incomplete treatment leads to poor therapeutics responses and promotes drug resistance. Simultaneous combinat ...
... There are different ways to combine antimalarial drugs. Compliance with sequential combination regimen is notoriously poor; patients are reluctant to take antimalarials after they feel well. Incomplete treatment leads to poor therapeutics responses and promotes drug resistance. Simultaneous combinat ...
Product Monograph
... The effects of leuprolide acetate on bone lesions may be monitored by bone scans, while its effects on prostatic lesions may be monitored by ultrasonography and/or computed tomography (CT) scan in addition to digital rectal examination. Intravenous pyelogram, ultrasonography, or CT scan may also be ...
... The effects of leuprolide acetate on bone lesions may be monitored by bone scans, while its effects on prostatic lesions may be monitored by ultrasonography and/or computed tomography (CT) scan in addition to digital rectal examination. Intravenous pyelogram, ultrasonography, or CT scan may also be ...
METHOTREXATE 25 MG/ML SOLUTION FOR INJECTION
... common dosages and therapy protocols, which have proved to be efficacious in the therapy of the disorder in each case, are given below. Furthermore, several different polychemotherapies involving methotrexate have proved efficacious for the various indications for high-dose methotrexate therapy. Non ...
... common dosages and therapy protocols, which have proved to be efficacious in the therapy of the disorder in each case, are given below. Furthermore, several different polychemotherapies involving methotrexate have proved efficacious for the various indications for high-dose methotrexate therapy. Non ...
Cytochrome P450 2D6 (CYP2D6) Pharmacogenetic
... plasma concentrations of the drug and likely therapeutic failure b) The patient should not receive amitriptyline due to increased plasma concentrations of the drug and likely development of side effects c) There is no reason to adjust the dose of amitriptyline based on the CYP2D6 genotype test resul ...
... plasma concentrations of the drug and likely therapeutic failure b) The patient should not receive amitriptyline due to increased plasma concentrations of the drug and likely development of side effects c) There is no reason to adjust the dose of amitriptyline based on the CYP2D6 genotype test resul ...
Cytochrome P450 2D6 (CYP2D6) Pharmacogenetic Competency
... plasma concentrations of the drug and likely therapeutic failure b) The patient should not receive amitriptyline due to increased plasma concentrations of the drug and likely development of side effects c) There is no reason to adjust the dose of amitriptyline based on the CYP2D6 genotype test resul ...
... plasma concentrations of the drug and likely therapeutic failure b) The patient should not receive amitriptyline due to increased plasma concentrations of the drug and likely development of side effects c) There is no reason to adjust the dose of amitriptyline based on the CYP2D6 genotype test resul ...
Mepivacaine - Academy of General Dentistry
... declined but remained the third most used agent.2 Mepivacaine’s niche has been considered by many dentists to be the “safer” lidocaine alternative, to be used in elderly or cardiovascular disease patients, because it not only comes without a vasoconstrictor, but it is available with levonordefrin, w ...
... declined but remained the third most used agent.2 Mepivacaine’s niche has been considered by many dentists to be the “safer” lidocaine alternative, to be used in elderly or cardiovascular disease patients, because it not only comes without a vasoconstrictor, but it is available with levonordefrin, w ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.